P. Wells-Jordan

Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

C. Richards, D. Fennell, C. Brookes, 2021, The Lancet. Respiratory medicine.

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

C. Richards, D. Fennell, C. Brookes, 2022, The Lancet. Oncology.

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

C. Swanton, F. Dudbridge, G. Wilson, 2021, Nature Communications.

A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis

G. Saldanha, J. Pringle, T. de Haro, 2016, Melanoma research.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

C. Richards, D. Fennell, P. Szlosarek, 2021, The Lancet. Oncology.

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

M. Zhang, C. Swanton, F. Dudbridge, 2021, Nature Communications.

PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

C. Richards, D. Fennell, P. Szlosarek, 2021 .